Skip to main content
Premium Trial:

Request an Annual Quote

Triad Biotechnology Buys Cerius 2 Software From Molecular Simulations

Premium

SAN DIEGO--Triad Biotechnology recently purchased software from Pharmacopeia subsidiary Molecular Simulations (MSI). Triad will use MSI's Cerius 2 modeling software to assist its research efforts in structural genomics-based drug discovery. Triad said it plans to engineer antimicrobial drug candidates to leverage the availability of recently released microbial genomic information and address growing drug resistance observed in microbes such as Mycobacterium tuberculosis, Staphylococcus aureus, and Helicobacter pylori. Daniel Sem, Triad's vice-president for biophysics, said, "MSI's Cerius 2 modeling software will play a pivotal role in helping Triad engineer desired changes into molecules without losing their already advantageous properties."

Filed under

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.